Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viekira Pak + Ribavirin in HCV Genotype 1 on Opioid Replacement Therapy
NCT01911845Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2013
- Primary completion
- Dec 2013
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of paritaprevir, ombitasvir and dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment. Started Apr 2013; status: completed.
02
Drugs
paritaprevirombitasvirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01911845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01911845.